MENU
+Compare
SYNB
ETF ticker: NYSE ARCA
AS OF
Oct 14 closing price
Price
$30.61
Change
+$0.06 (+0.20%)
Net Assets
5.39M

SYNB stock forecast, quote, news & analysis

The investment seeks long term capital appreciation... Show more

Category: #Health
SYNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
A.I.Advisor
published price charts
These past five trading days, the ETF lost 0.00% with an average daily volume of 0 shares traded.The ETF tracked a drawdown of 0% for this period.
Interact to see
Advertisement
A.I.Advisor
a Summary for SYNB with price predictions
Oct 16, 2025

SYNB's Stochastic Oscillator dives into oversold zone

The Stochastic Oscillator for SYNB moved into oversold territory on October 16, 2025. Be on the watch for the price uptrend or consolidation in the future. At that time, consider buying the stock or exploring call options.

Price Prediction Chart

Technical Analysis (Indicators)

Bullish Trend Analysis

SYNB moved above its 50-day moving average on October 01, 2025 date and that indicates a change from a downward trend to an upward trend.

The 10-day moving average for SYNB crossed bullishly above the 50-day moving average on October 03, 2025. This indicates that the trend has shifted higher and could be considered a buy signal. In of 9 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are .

Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where SYNB advanced for three days, in of 162 cases, the price rose further within the following month. The odds of a continued upward trend are .

SYNB may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The 10-day RSI Indicator for SYNB moved out of overbought territory on October 10, 2025. This could be a bearish sign for the stock. Traders may want to consider selling the stock or buying put options. Tickeron's A.I.dvisor looked at 21 similar instances where the indicator moved out of overbought territory. In of the 21 cases, the stock moved lower in the following days. This puts the odds of a move lower at .

The Momentum Indicator moved below the 0 level on October 15, 2025. You may want to consider selling the stock, shorting the stock, or exploring put options on SYNB as a result. In of 49 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for SYNB turned negative on October 16, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 25 similar instances when the indicator turned negative. In of the 25 cases the stock turned lower in the days that followed. This puts the odds of success at .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where SYNB declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for SYNB entered a downward trend on September 30, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

A.I.Advisor
published Highlights

Notable companies

The most notable companies in this group are NVIDIA Corp (NASDAQ:NVDA), Alphabet (NASDAQ:GOOGL), Eli Lilly & Co (NYSE:LLY), ABBVIE (NYSE:ABBV), AstraZeneca PLC (NASDAQ:AZN), ZOETIS (NYSE:ZTS), Regeneron Pharmaceuticals (NASDAQ:REGN), DuPont de Nemours (NYSE:DD), Biogen (NASDAQ:BIIB), Exact Sciences Corp (NASDAQ:EXAS).

Industry description

The investment seeks long term capital appreciation. The fund invests mainly in common stocks (growth or value stocks or both) of companies worldwide of any size with a focus on “biology revolution” companies. From time to time, the fund may invest a significant portion of its assets in companies in one or more related industries or sectors, including the health care, consumer discretionary, consumer staples, biotechnology and materials sectors. The fund is non-diversified.

Market Cap

The average market capitalization across the Putnam BioRevolution ETF ETF is 249.56B. The market cap for tickers in the group ranges from 431.62M to 4.43T. NVDA holds the highest valuation in this group at 4.43T. The lowest valued company is RCKT at 431.62M.

High and low price notable news

The average weekly price growth across all stocks in the Putnam BioRevolution ETF ETF was -2%. For the same ETF, the average monthly price growth was 1%, and the average quarterly price growth was 17%. BG experienced the highest price growth at 17%, while CRSP experienced the biggest fall at -9%.

Volume

The average weekly volume growth across all stocks in the Putnam BioRevolution ETF ETF was 5%. For the same stocks of the ETF, the average monthly volume growth was 14% and the average quarterly volume growth was -27%

Fundamental Analysis Ratings

The average fundamental analysis ratings, where 1 is best and 100 is worst, are as follows

Valuation Rating: 60
P/E Growth Rating: 66
Price Growth Rating: 50
SMR Rating: 100
Profit Risk Rating: 67
Seasonality Score: 35 (-100 ... +100)
View a ticker or compare two or three
SYNB
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published General Information

General Information

Category Health

Profile
Fundamentals
Details
Category
Health
Address
Putnam ETF Trus100 FEDERAL STREET
Phone
6177601060
Web
N/A